Uptake of Pneumococcal Conjugate Vaccine: Methodological Issues in Measurement and Impact of Publicly Funded Programs

This publication has 9 references indexed in Scilit:

• Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada
  The Pediatric Infectious Disease Journal, 2008
• Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA
  Expert Review of Vaccines, 2008
• National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2006.
  2007
• Cost-Effectiveness of Pneumococcal Conjugate Vaccine
  The Pediatric Infectious Disease Journal, 2006
• Disparities in varicella vaccine coverage in the absence of public funding
  Vaccine, 2005
• Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
  New England Journal of Medicine, 2003
• An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
  2002
• Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults11The names and affiliations of the Task Force members are listed on page v of this supplement and at http://www.thecommunityguide.org22Some of this material was published previously in: Shefer A, Briss P, Rodewald L, et al. Improving immunization coverage rates: an evidence-based review of the literature. Epidemiol Rev 1999;20:96–142.
  American Journal of Preventive Medicine, 2000
• Pneumococcal Immunization Program in Montérégie, Québec: Feasibility Study
  Canadian Journal of Infectious Diseases, 1999